本文選題：依托泊苷 + 乳腺腫瘤　； 參考：《腫瘤防治研究》2017年05期

【摘要】：目的評(píng)價(jià)口服依托泊苷治療轉(zhuǎn)移性乳腺癌的療效和不良反應(yīng)。方法回顧性分析88例接受口服依托泊苷治療的轉(zhuǎn)移性乳腺癌患者資料�？诜劳胁窜�50 mg/d,d1~20,每28天為一周期。結(jié)果共納入88例乳腺癌患者,83.0%(73/88)為三線以上治療,78.4%(69/88)既往用蒽環(huán)類、紫杉類藥物及卡培他濱治療過。88例患者采用口服依托泊苷方案中位化療5周期,均可評(píng)價(jià)療效,其中部分緩解(PR)7例(8.0%),疾病穩(wěn)定(SD)50例(56.8%),疾病進(jìn)展(PD)31例(35.2%),無完全緩解(CR)患者。客觀緩解率(CR+PR)為8.0%,臨床獲益率(CR+PR+SD≥6.0月)為44.3%。整體中位無進(jìn)展生存期(PFS)為5.0月(95%CI:3.8~6.2月),中位生存期(OS)為17.0月(95%CI:11.3~22.7月)。主要不良反應(yīng)為1~2級(jí)惡心18例(20.5%),1~2級(jí)中性粒細(xì)胞減少19例(21.6%),3級(jí)中性粒細(xì)胞減少3例(3.4%)。結(jié)論口服依托泊苷治療難治性轉(zhuǎn)移性乳腺癌耐受性好、有一定療效。
[Abstract]:Objective to evaluate the efficacy and adverse effects of oral etoposide in the treatment of metastatic breast cancer. Methods 88 patients with metastatic breast cancer received oral etoposide therapy were retrospectively analyzed. Oral etoposide 50 mg / d 1 C 20, every 28 days for a cycle. Results A total of 88 breast cancer patients (83.0% / 88) were treated with anthracyclines (78.489% / 88), yew drugs and capecitabine for 5 cycles of oral etoposide regimen (median chemotherapy). Among them, there were 7 cases of PRD with partial remission, 50 cases of SDN with disease stability and 56.8%, and 31 cases with PDD with no complete remission. The objective remission rate (CR) was 8.0 and the clinical benefit rate (CR PR SD 鈮，

本文編號(hào)：1778233